Comparative Pharmacology
Head-to-head clinical analysis: IMDUR versus MONOKET.
Head-to-head clinical analysis: IMDUR versus MONOKET.
IMDUR vs MONOKET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isosorbide mononitrate is a nitrate vasodilator that relaxes vascular smooth muscle via conversion to nitric oxide (NO), which activates guanylate cyclase, increasing cGMP levels, leading to vasodilation. It primarily dilates veins (venodilation) with lesser effects on arteries, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Isosorbide mononitrate is a vasodilator that relaxes vascular smooth muscle via the release of nitric oxide (NO), which activates guanylate cyclase, increasing intracellular cGMP. This leads to venous and arterial dilation, reducing preload and afterload, thereby decreasing myocardial oxygen demand.
Initial: 30-60 mg orally once daily; titrate to 120 mg once daily as tolerated. Maximum: 240 mg once daily.
20 mg orally twice daily, 7 hours apart (e.g., 8 AM and 3 PM) to provide a nitrate-free interval.
None Documented
None Documented
Terminal elimination half-life of isosorbide mononitrate is approximately 5 hours. This supports once-daily dosing for IMDUR (extended-release formulation) due to prolonged absorption phase.
Terminal elimination half-life is approximately 5 hours (range 4–6 hours) for isosorbide mononitrate, consistent with a sustained duration suitable for once-daily dosing.
Isosorbide dinitrate (IMDUR active metabolite? Actually IMDUR is isosorbide mononitrate, the active metabolite of isosorbide dinitrate. For isosorbide mononitrate: renal excretion is approximately 96% as metabolites, with about 2% unchanged; biliary/fecal excretion is minimal, <2%.
Renal: approximately 98% of the dose is excreted in urine as metabolites (isosorbide mononitrate and its glucuronide conjugates); fecal excretion is minimal (<2%).
Category C
Category C
Nitrate Vasodilator
Nitrate Vasodilator